Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Change in Account Payables (2016 - 2020)

Alterity Therapeutics has reported Change in Account Payables over the past 4 years, most recently at -$413122.1 for Q4 2018.

  • For Q4 2018, Change in Account Payables rose 87.27% year-over-year to -$413122.1; the TTM value through Dec 2018 reached -$4.3 million, up 3.93%, while the annual FY2025 figure was -$1.3 million, 283.3% down from the prior year.
  • Change in Account Payables for Q4 2018 was -$413122.1 at Alterity Therapeutics, down from $8802.9 in the prior quarter.
  • Over five years, Change in Account Payables peaked at $8802.9 in Q2 2018 and troughed at -$5.1 million in Q4 2015.
  • A 4-year average of -$1.4 million and a median of -$413122.1 in 2018 define the central range for Change in Account Payables.
  • Biggest five-year swings in Change in Account Payables: crashed 1065.61% in 2017 and later soared 101.37% in 2018.
  • Year by year, Change in Account Payables stood at -$5.1 million in 2015, then skyrocketed by 94.57% to -$278480.6 in 2016, then crashed by 1065.61% to -$3.2 million in 2017, then skyrocketed by 87.27% to -$413122.1 in 2018.
  • Business Quant data shows Change in Account Payables for ATHE at -$413122.1 in Q4 2018, $8802.9 in Q2 2018, and -$3.2 million in Q4 2017.